Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression



Status:Recruiting
Conditions:Depression
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:4/21/2016
Start Date:April 2013
End Date:April 2016
Contact:Max Martinson
Email:mmartinson@partners.org
Phone:617-724-2784

Use our guide to learn which trials are right for you!

Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

This study is looking at the safety and efficacy of low field magnetic stimulation (LFMS)
for treating patients with treatment resistant depression who are taking an antidepressant
that is not working for them.


Inclusion Criteria:

- Male or female, 18-65 years old

- Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major
Depressive Episode (MDE) of at least eight weeks

- A participant has Treatment Resistant Depression (TRD) of the current MDE

- Good general health

- For female participants, status of non-childbearing potential or use of an acceptable
form of birth control

- Body mass index between 18-40 kg/m2

- Concurrent psychotherapy will be allowed if the type and frequency of the therapy has
been stable for at least three months prior to screening and is expected to remain
stable during participation in the study

- Concurrent hypnotic therapy will be allowed if the therapy has been stable for at
least 4 weeks prior to screening and is expected to remain stable during the
subject's participation in the study

- Participant must be able to lie flat for 20 minutes

Exclusion Criteria:

- A woman of childbearing potential who is not willing to use one of the specified
forms of birth control during the study

- Pregnant or breastfeeding

- A woman with a positive pregnancy test at screening or baseline

- Participant has TRD of the current MDE with failure to achieve a satisfactory
response, as perceived by the subject, to more than 3 treatment courses of a
therapeutic dose of an antidepressant therapy of at least eight weeks duration

- Participant has a current diagnosis of a Substance Use Disorder with the exception of
nicotine dependence, at screening or within six months prior to screening

- Current diagnosis of Axis I disorders other than Generalized Anxiety Disorder, Social
Anxiety Disorder, Panic Disorder, Specific Phobia, Post Traumatic Stress Disorder or
Complicated Grief (unless one of these is comorbid and clinically unstable, and/or
the focus of the participant's treatment for the past six months or more).

- Subject has a history of schizophrenia or schizoaffective disorders, any history of
psychotic symptoms or is on antipsychotic medication for the treatment of psychotic
symptoms

- Subject has a history of eating disorders within five years of screening

- Subject has any Axis I or Axis II Disorder, which at screening is clinically
predominant to their MDD or has been predominant at any time within six months prior
to screening

- The participant is considered at significant risk for suicide during the study

- Subject has had electroconvulsive therapy in the current episode of depression

- Subject has had Transcranial Magnetic Stimulation or has received treatment with
other experimental devices for the treatment of the current episode of depression

- Subject has received Vagus Nerve Stimulation at any time

- Dementia, delirium, amnestic, or other cognitive disorders

- There is a clinically significant abnormality on the screening physical examination

- Participation in any clinical trial with an investigational drug or device within the
past month or concurrent to study participation

- Known history or current episode of:

--Uncontrolled hypertension, Recent myocardial infarction (within one year) or a
history of more than one myocardial infarction, Syncopal event within the past year,
Congestive heart failure, Angina pectoris

- Lifetime history of surgical procedures involving the brain or meninges,
encephalitis, meningitis, degenerative central nervous system disorder (e.g.,
Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, any other
disease/procedure/accident/intervention associated with significant injury to or
malfunction of the central nervous system, or a history of significant head trauma
within the past two years.

- Lab abnormalities are present

- History of hypothyroidism and has been on a stable dosage of thyroid replacement
medication for less than six months prior to screening

- Hisotry of hyperthyroidism which was treated (medically or sugically) less than six
months prior to screening

- Any current or past history of any physical condition which in the investigator's
opinion might put the subject at risk or interfere with the interpretation of study
results

- History of positive screening urine test for drugs of abuse

- Patient with any non-removable stimulation device such as neurostimulators,
pacemakers and cochlear implants

- Patients requiring treatment with excluded concomitant medications

- Patients who cannot be in a MRI

- Patients who are currently using a metal intrauterine device (IUD)
We found this trial at
6
sites
New York, New York 10029
Principal Investigator: Dan Iosifescu, MD
Phone: 212-241-6349
?
mi
from
New York, NY
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Mark Rapaport, MD
Phone: 404-727-8966
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Richard Shelton, MD
Phone: 205-975-0068
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: George I Papakostas, MD
Phone: 617-724-3673
?
mi
from
Boston, MA
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Madhukar Trivedi, MD
Phone: 214-648-0174
?
mi
from
Dallas, TX
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Principal Investigator: Gerald Sanacora, MD, PhD
Phone: 203-974-7528
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials